Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | CCR1 | P32246 | 2/20 | 0.41 |
| ▸ | CCR5 | P51681 | 2/20 | 0.41 |
| ▸ | CCR8 | P51685 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | METAP1 | P53582 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.41 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 3/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5573941 | 0.98 | KDM4E (0.39) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL31143546 | 0.83 | KDM4E (0.41) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL30025575 | 0.83 | KDM4E (0.44) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL14357960 | 0.83 | KDM4E (0.44) | KDM4ELMNACCR1CCR5CCR8 | |
| Acetic Acid SCHEMBL28009762 | 0.76 | PDE4A (0.48) | KDM4ELMNACYP1A2HIF1AP4HTM | |
| SCHEMBL3645535 | 0.74 | KDM4E (0.44) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL29388428 | 0.74 | KDM4E (0.44) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL826368 | 0.74 | KDM4E (0.44) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL1426644 | 0.73 | KDM4E (0.40) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL10337588 | 0.73 | LMNA (0.41) | KDM4ELMNACCR1CCR5CCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117223143-A | Nonaqueous electrolyte and nonaqueous secondary battery | 旭化成株式会社 | 2023-12-12 | — | — | CN | disclosed |
| CN-116056697-A | 2-oxo-oxazolidine-5-carboxamides as NAV1.8 inhibitors | 默沙东有限责任公司 | 2023-05-02 | — | — | CN | disclosed |
| WO-2020038433-A1 | EGFR KINASE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 上海艾力斯医药科技有限公司 | 2020-02-27 | — | — | WO | disclosed |
| CN-110642838-A | EGFR inhibitor and preparation and application thereof | 江苏威凯尔医药科技有限公司 | 2020-01-03 | — | — | CN | disclosed |
| WO-2019238103-A1 | PREPARATION METHOD FOR PYRIDINYLAMINOPYRIMIDINE DERIVATIVE AND INTERMEDIATE THEREOF | 上海艾力斯医药科技有限公司 | 2019-12-19 | — | — | WO | disclosed |
| CN-104520296-A | Pyrrolopyridinone derivatives as TTX-S blockers | RAQUALIA PHARMA INC | 2015-04-15 | — | — | CN | disclosed |
| CN-100404529-C | 2, 4-bis (trifluoroethoxy) pyridine compound and medicine containing the same | KOWA CO (JP) | 2008-07-23 | — | — | CN | disclosed |
| EP-1838314-A1 | PROCESS FOR PREPARING LANSOPRAZOLE | KRKA, tovarna zdravil, d.d., Novo mesto (SI) | 2007-10-03 | — | — | EP | disclosed |
| US-7223764-B2 | 2,4-bis (trifluoroethoxy)pyridine compound and drug containing the compound | KOWA CO., LTD. (JP) | 2007-05-29 | — | — | US | disclosed |
| CN-1816542-A | 2, 4-bis (trifluoroethoxy) pyridine compound and medicine containing the same | KOWA CO (JP) | 2006-08-09 | — | — | CN | disclosed |
| WO-2006074952-A1 | PROCESS FOR PREPARING LANSOPRAZOLE | KRKA, TOVARNA ZDRAVIL, D.D., NOVO MESTO (SI) | 2006-07-20 | — | — | WO | disclosed |
| US-20050020606-A1 | 2,4-Bis (trifluoroethoxy)pyridine compound and drug containing the compound | KOWA CO., LTD. (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-0944617-A1 | CRYSTALS OF BENZIMIDAZOLE DERIVATIVES AND THEIR PRODUCTION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-09-29 | — | — | EP | disclosed |
| WO-1998021201-A1 | CRYSTALS OF BENZIMIDAZOLE DERIVATIVES AND THEIR PRODUCTION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020606-A1 | 2,4-Bis (trifluoroethoxy)pyridine compound and drug containing the compound | ACAT2, ACAT1, CYP7A1 | KDM4E 1096/4885LMNA 4487/4885CCR1 3519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.